Cellular and Molecular Gastroenterology and Hepatology · 2021 · 109 citations · 43 references
Life SciencesGeneticsMolecular GeneticsCancer GeneticsCarcinogenesisGene ExpressionBiomarkers Of Liver InjuryHepatic PathophysiologyGenetic Liver DiseaseGenetic Risk VariantsHepatocellular Carcinoma PathogenesisLiver Injury ModelsMetabolic Pathway PolymorphismsRisk Gene VariantsTransmembrane DomainsTransmembrane Proteins
BACKGROUND & AIMS: cells. METHODS: ) through Clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9). RESULTS: cells also showed the highest proliferation rate. Finally, the re-overexpression of MBOAT7 and/or TM6SF2 reversed the metabolic and tumorigenic features observed in the compound knockout model. CONCLUSIONS: The co-presence of the 3 at-risk variants impacts the NAFLD course in both patients and experimental models, affecting LD accumulation, mitochondrial functionality, and metabolic reprogramming toward HCC.
43
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran, Patrick D. Hsu, Jason Wright et al. · Nature Protocols · 2013 · 11.7K citations · Full text
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations
An integrated map of genetic variation from 1,092 human genomes
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo, Julia Kozlitina, Chao Xing et al. · Nature Genetics · 2008 · 3.4K citations · Full text